Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis

Trial Profile

A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inebilizumab (Primary) ; Inebilizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 31 Oct 2021 Results (n=213) assessing population pharmacokinetic modeling of inebilizumab from a pivotal study (NCT02200770) in adult subjects with neuromyelitis optica spectrum disorders and two early-stage studies (NCT00946699 and NCT01585766) in subjects with systemic sclerosis or relapsing multiple sclerosis were pooled and simultaneously analyzed using a population approach, published in the Clinical Pharmacokinetics.
    • 29 Oct 2018 Results published in the ClinicalTrials.gov: US National Institutes of Health Registry.
    • 15 Aug 2016 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top